212 related articles for article (PubMed ID: 35962459)
1. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments.
Jemaa S; Paulson JN; Hutchings M; Kostakoglu L; Trotman J; Tracy S; de Crespigny A; Carano RAD; El-Galaly TC; Nielsen TG; Bengtsson T
Cancer Imaging; 2022 Aug; 22(1):39. PubMed ID: 35962459
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
[TBL] [Abstract][Full Text] [Related]
4. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
5. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
7. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Overall Survival and Progression-Free Survival by the
Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
[No Abstract] [Full Text] [Related]
9. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
10. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [
Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227
[TBL] [Abstract][Full Text] [Related]
11.
Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
[TBL] [Abstract][Full Text] [Related]
12. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
13. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
15. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
17. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.
Broecker-Preuss M; Becher-Boveleth N; Müller SP; Hüttmann A; Hanoun C; Grafe H; Richter J; Klapper W; Rekowski J; Bockisch A; Dührsen U
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2611-2621. PubMed ID: 34708297
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.
Aide N; Talbot M; Fruchart C; Damaj G; Lasnon C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):699-711. PubMed ID: 29214417
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
20. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]